Clinical pharmacogenetics in pediatric patients

Pharmacogenomics

Volumn 8, Issue 10, 2007, Pages 1403-1411

  Husain, Anwar ^a   Loehle, Jennifer A ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Attention deficit hyperactivity disorder; Childhood leukemia; Pediatrics; Pharmacogenetics; Pharmacogenomics; Transplantation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLOSPORIN; CYTOCHROME P450 1A1; GLUCOCORTICOID; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; METHYLPHENIDATE; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TRANSCRIPTION FACTOR T BET; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATTENTION DEFICIT DISORDER; BLOOD TOXICITY; BONE DENSITY; BRONCHODILATATION; CHILD; CHILD CARE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GRAFT REJECTION; GROWTH INHIBITION; GROWTH RATE; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRRITABILITY; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL CARE; MONOTHERAPY; MOTOR DYSFUNCTION; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TACHYPHYLAXIS; TIC; UNSPECIFIED SIDE EFFECT; UTILIZATION REVIEW;

ASTHMA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG THERAPY; HUMANS; LEUKEMIA; ORGAN TRANSPLANTATION; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 36448971304     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.10.1403     Document Type: Review

References (65)

1. Kearns GL, Abdel-Rahman SM, Alander SW et al.: Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
2. Leeder JS: Developmental and pediatric pharmacogenomics. Pharmacogenomics 4, 331-341 (2003).
3. Hines RN, McCarver DG: The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300, 355-60 (2002).
4. McCarver DG, Hines RN: The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol. Exp. Ther. 300, 361-366 (2002).
5. Need AC, Motulsky AG, Goldstein DB: Priorities and standards in pharmacogenetic research. Nat. Genet. 37, 671-681 (2005).
6. Haffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
7. Cascorbi I. Gerloff T, Johne A et al.: Frequency of single nucleotide, polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69, 169-174 (2001).
8. Hitzl M, Drescher S, van der Kulp H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11, 293-298 (2001).
9. Tanabe M, Ieiri I. Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism. of the multidrug resistance (MDR). J. Pharmacol. Exp. Ther. 297(3), 1137-1143 (2001).
10. von Ahsen N, Richter M, Grupp C. et al.: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism ( CYP3A4-V allele). Clin. Chem. 47(6), 1048-1052 (2001).
11. Zheng H, Webber S, Zeevi A et al.: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. 63, 765-70 (2002).
12. Carroll WL, Bhojwani D, Min DJ et al.: Pediatric acute lymphoblastic leukemia. Hematology Am. Soc. hematol. Educ. Program 102-131 (2003).
13. Silverman LB, Sallan SE: Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr. Opin. hematol. 10, 290-296 (2003).
14. Rocha JC, Cheng C, Liu W et al.: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105, 4752-4758 (2005).
15. Krajinovic MD, Labuda D, Richer C, Karimi S, Sinnett D: Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93, 1496-1501 (1999).
16. Krajinovic MD, Labuda D, Mathonnet G, et al.: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancar Res. 8, 802-810 (2002).
17. Balta G, Yusek N, Ozyurek E et al.: Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am. J. hematol. 73, 154-160 (2003).
18. Meissner B, Stanulla M, Ludwig WM et al.: The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia 18, 1920-1923 (2004).
19. Kishi S, Yang W, Boureau B et al.: Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103, 67-72 (2004).
20. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K: Polymarphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95(4) 1222-1228 (2000).
21. Stanulla M, Schaffeier E, Arens S et al.: GSTP1 and MDR1 genotypes and central nervous-sys6m relapse in childhood acute lymphoblastic leukemia. Int J. Hematol. 81 39-44 (2005).
22. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990).
23. Evans WE, Horner M. Chu YQ. Kalwinski D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119. 985-989 (1991).
24. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91, 2001-2008 (1999).
25. Relling MV, Yanishevski Y, Nemec J et al.: Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12, 346-352 (1998).
26. Bo J, Schroder H, Kristinsson J et al.: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells:. relation to thiopurine metabolism. Cancer 1080-1086 (1999).
27. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacagenomics J. 4, 66-72 (2004).
28. Aplenc R, Thompson J, Han P et al.: Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 65, 2482-2487 (2005).
29. Costea I, Moghrabi A, Laverdiere C, Graziani A. Krajinovic M: Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 91, 1113-1116 (2006).
30. Drazen JM, Silverman EK, Lee TH: Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56, 1054-70 (2000).
31. Lanes SF, Garcia Rodríguez LA, Huerta C: Respiratory medications and risk of asthma death. Thorax 57, 683-6 (2002).
32. Szefler SJ, Phillips BR, Martinez FD et al.: Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115, 233-242 (2005).
33. Szefler SJ. Pediatric asthma: an approach to pharmacogenetics analysis. Chest 123, S434-S438 (2003).
34. Martinez FD, Graves PE, Baldini M, Solomon S, Ericsson R: Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100, 3184-3188 (1997).
35. Lima, JJ, Thomason DB. Mohamed MJ, Eberle LV, Self TH, Johnson JA: Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther 65, 519-25 (1999).
36. Israel E, Draen JM, Liggett SB et al.: The effect of polymorphisms of the β(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Raspir. Crit. Care Med. 162, 75-80 (2000).
37. Israel E, Chinchilli VM, Ford JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-aver trial. Lancet 364, 1505-1512 (2004).
38. Wechsler ME: Managing asthma in the 21st century: role of pharmacogenetics. Pediatr Ann. 35, 660-662 (2006).
39. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad Sci. USA 97, 10483-10488 (2000).
40. Tantisira KG, Lake S, Silverman ES et al.: Corticosterold pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13,1353-1359 (2004).
41. Tantisira KG, Hwang ES, Raby BA et al.: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl. Acad. USA 101, 18099-18104 (2004).
42. Drazen JM, Isrsael E, O'Byrne PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl. J. Med. 340, 197-206 (1999).
43. Drazen JM. Yandava CN, Dube L et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22, 168-170 (1999).
44. Lima JJ, Zhang S, Grant A et al.: Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir Crit. Care Med. 173,379-385 (2006).
45. Sampson AP Siddiqui S, Buchanan D et al.: Variant LTC (4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(Suppl. 2) S28-S31 (2000).
46. Asano KT Shiomi T. Hasegawa N et al.: Leukotriene C4 synthase gene A(-444) polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12, 565-570 (2002).
47. Whelan GJ, Blake K, Kissoon N et al.: Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444). Pediatr. Pulmonol. 36. 413-420 (2003).
48. Currie GP, Lima JJ, Sylvester JE, Lee KD, Cockburn WJ, Lipworth BJ: Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J. Clin. Pharmacol. 56, 422-426 (2003).
49. Kedda MA, Shi J, Duffy D, et al.: Characterization of two polymorphism in the leukotriene C4 synthase gene irran Australian population of subjects with mild, moderate, and severe asthma. J. Allergy Clin. Immunol. 113, 889-895 (2004).
50. Kirley A, Lowe N, Hawi Z et al.: Association of the A80 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121, 50-54 (2003).
51. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J: Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J. Child Adolesc. Psychopharmacol. 14, 564-74 (2004).
52. McGough JJ: Attention-deficit/hyperactivity disorder pharmacogenomics. Biol. Psychiatry 57, 1367-1373 (2005).
53. Winsberg BG, Comings DE: Association of the dopamine transporter gene (DAT1). J. Am. Acad. Child Adolesc. Psychiatry 38(12) 1474-1477 (1999).
54. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics 12, 497-499 (2002).
55. Cheon KA, Ryu YH, Kim JW, Cho DY: The homozygosity for 10 repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur. Neuropsychopharmacol. 15, 95-101 (2005).
56. Stein MA, Waldman ID, Sarampote CS et al.: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30, 1374-1382 (2005).
57. Langley KD, Turic D, Peirce TR et al.: No support for association between the dopamine transporter (DAT1) and ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139, 7-10 (2005).
58. van der Meulen EM, Bakker SC, Pauls DL et al.: High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J. Child Psychol. Psychiatry 46, 1074-1080 (2005).
59. van Tol, HH, Wu CM, Guan HC et al.: Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992).
60. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, van Tol HH: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
61. Zeni CP, Guimaraes AP, Polanczyk GV et al.: No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 391-394 (2007).
62. McGough J, McCracken J, Swanson J et al.: Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 45, 1314-1322 (2006).
63. Yang L, Wang YF, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry 43, 1154-1158 (2004).
64. Polanczyk G, Zeni C, Genro JP et al.: Association of the adrenergic α2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/ hyperactivity disorder. Arch. Gen. Psychiatry 64, 218-224 (2007).
65. Charach AA, Ickowicz A, Schachar R: Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J. Am. Acad. Child Adolesc. Psychiatry 43, 559-567 (2004).